FEDERLE, LISA
 Distribuzione geografica
Continente #
NA - Nord America 913
AS - Asia 93
EU - Europa 76
OC - Oceania 1
Totale 1.083
Nazione #
US - Stati Uniti d'America 912
CN - Cina 37
SG - Singapore 34
IT - Italia 21
SE - Svezia 15
VN - Vietnam 15
GB - Regno Unito 11
DE - Germania 9
RU - Federazione Russa 9
IN - India 7
FI - Finlandia 6
UA - Ucraina 2
AT - Austria 1
FR - Francia 1
HN - Honduras 1
IE - Irlanda 1
NZ - Nuova Zelanda 1
Totale 1.083
Città #
Fairfield 183
Ashburn 107
Woodbridge 92
Cambridge 73
Houston 59
Wilmington 58
Chandler 52
Seattle 50
Santa Clara 42
Singapore 28
Ann Arbor 22
San Diego 16
Dong Ket 15
Boardman 14
Medford 10
Princeton 10
Padova 9
Roxbury 9
Des Moines 8
Beijing 7
Los Angeles 6
Helsinki 5
London 4
Nanchang 4
New York 4
Moscow 3
Norwalk 3
Guangzhou 2
Jiaxing 2
Kunming 2
Munich 2
Rome 2
Tianjin 2
Vicenza 2
Washington 2
Acton 1
Borås 1
Clifton 1
Dublin 1
Frankfurt am Main 1
Hebei 1
Jinan 1
Kilburn 1
Labico 1
Leawood 1
Nanjing 1
Nuremberg 1
Phoenix 1
Pinehaven 1
Pune 1
Radeberg 1
Shenyang 1
Tegucigalpa 1
Villafranca Padovana 1
Totale 928
Nome #
BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset 141
Decreased platelet number in multiple sclerosis during alemtuzumab infusion: A common, transient and clinically silent phenomenon 133
Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset 129
Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy 127
Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset 106
Hyperreflective Foci in the Retina of Active Relapse-Onset Multiple Sclerosis 106
Acute simultaneous development of brain tumour–like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis 102
BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset 85
Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis 78
NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis 73
Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review 19
Totale 1.099
Categoria #
all - tutte 4.421
article - articoli 4.421
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.842


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202097 0 0 0 0 0 0 0 27 23 17 22 8
2020/2021267 9 18 16 13 6 1 3 17 10 116 26 32
2021/2022167 2 12 19 14 18 21 11 18 5 2 12 33
2022/2023120 16 13 2 14 14 16 1 9 26 0 5 4
2023/202475 2 13 13 6 5 16 2 3 0 7 4 4
2024/2025122 1 14 12 16 59 3 15 2 0 0 0 0
Totale 1.099